Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML)
We evaluated pazopanib (800 mg orally QD) in patients not eligible for intensive treatment with relapsed/refractory AML or at initial diagnosis. Patients receiving pazopanib for > 14 days were analyzed for safety, tolerability, and efficacy. Co-primary endpoints were cumulative response rate and...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
21 March 2019
|
| In: |
Annals of hematology
Year: 2019, Jahrgang: 98, Heft: 6, Pages: 1393-1401 |
| ISSN: | 1432-0584 |
| DOI: | 10.1007/s00277-019-03651-9 |
| Online-Zugang: | Verlag, Pay-per-use, Volltext: https://doi.org/10.1007/s00277-019-03651-9
|
| Verfasserangaben: | Torsten Kessler, Steffen Koschmieder, Christoph Schliemann, Martina Crysandt, Jan-Henrik Mikesch, Saskia von Stillfried, Matthias Stelljes, Michele Pohlen, Georg Lenz, Anna Kirsch, Kerstin Vehring, Eva Wardelmann, Wolfgang Hartmann, Eike Bormann, Joachim Gerss, Tim H. Brümmendorf, Carsten Müller-Tidow, Wolfgang E. Berdel |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1667485679 | ||
| 003 | DE-627 | ||
| 005 | 20230427035337.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190614s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00277-019-03651-9 |2 doi | |
| 035 | |a (DE-627)1667485679 | ||
| 035 | |a (DE-599)KXP1667485679 | ||
| 035 | |a (OCoLC)1341228073 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Keßler, Torsten |d 1968- |e VerfasserIn |0 (DE-588)115856757 |0 (DE-627)691638993 |0 (DE-576)290116457 |4 aut | |
| 245 | 1 | 0 | |a Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML) |c Torsten Kessler, Steffen Koschmieder, Christoph Schliemann, Martina Crysandt, Jan-Henrik Mikesch, Saskia von Stillfried, Matthias Stelljes, Michele Pohlen, Georg Lenz, Anna Kirsch, Kerstin Vehring, Eva Wardelmann, Wolfgang Hartmann, Eike Bormann, Joachim Gerss, Tim H. Brümmendorf, Carsten Müller-Tidow, Wolfgang E. Berdel |
| 246 | 3 | 0 | |a two |
| 264 | 1 | |c 21 March 2019 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 14.06.2019 | ||
| 520 | |a We evaluated pazopanib (800 mg orally QD) in patients not eligible for intensive treatment with relapsed/refractory AML or at initial diagnosis. Patients receiving pazopanib for > 14 days were analyzed for safety, tolerability, and efficacy. Co-primary endpoints were cumulative response rate and reduction of bone marrow microvessel density. Twenty patients (median age 76 years, range 52-86) were treated. Fifteen had relapsed/refractory and five had newly diagnosed AML. Median ECOG performance status was 1 (range 1-3). Four patients had adverse, 15 intermediate, and 1 patient favorable cytogenetic/molecular risk (ELN 2010 criteria). The safety profile of pazopanib was as reported. The most common adverse events of any grade were gastrointestinal. Two patients achieved PR (blast reduction > 50%), 14 stable disease (SD), and 4 progressive disease. Median PFS was 65 days (95% CI 29-105). After the end of the study, 1 CRi and 1 CRp occurred on demethylating agents, and 1 CR upon alloSCT. In these patients, SD and improved general condition on pazopanib allowed therapy escalation. Median OS for the overall study population was 191 days (95% CI 87-435) and 1-year survival was 35%. There was no significant change in microvessel density. Clinical trial information: NCT01361334. | ||
| 650 | 4 | |a Acute myeloid leukemia | |
| 650 | 4 | |a AML | |
| 650 | 4 | |a Pazopanib | |
| 650 | 4 | |a Phase II study | |
| 700 | 1 | |a Müller-Tidow, Carsten |d 1968- |e VerfasserIn |0 (DE-588)1015101798 |0 (DE-627)705330230 |0 (DE-576)351197893 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of hematology |d Berlin : Springer, 1991 |g 98(2019), 6, Seite 1393-1401 |h Online-Ressource |w (DE-627)253389852 |w (DE-600)1458429-3 |w (DE-576)072283157 |x 1432-0584 |7 nnas |a Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML) |
| 773 | 1 | 8 | |g volume:98 |g year:2019 |g number:6 |g pages:1393-1401 |g extent:9 |a Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML) |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00277-019-03651-9 |x Verlag |x Resolving-System |z Pay-per-use |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190614 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 1015101798 |a Müller-Tidow, Carsten |m 1015101798:Müller-Tidow, Carsten |d 910000 |d 910100 |e 910000PM1015101798 |e 910100PM1015101798 |k 0/910000/ |k 1/910000/910100/ |p 17 | ||
| 999 | |a KXP-PPN1667485679 |e 3487198630 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 14.06.2019"],"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"21 March 2019"}],"title":[{"title_sort":"Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML)","title":"Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML)"}],"id":{"eki":["1667485679"],"doi":["10.1007/s00277-019-03651-9"]},"name":{"displayForm":["Torsten Kessler, Steffen Koschmieder, Christoph Schliemann, Martina Crysandt, Jan-Henrik Mikesch, Saskia von Stillfried, Matthias Stelljes, Michele Pohlen, Georg Lenz, Anna Kirsch, Kerstin Vehring, Eva Wardelmann, Wolfgang Hartmann, Eike Bormann, Joachim Gerss, Tim H. Brümmendorf, Carsten Müller-Tidow, Wolfgang E. Berdel"]},"physDesc":[{"extent":"9 S."}],"relHost":[{"titleAlt":[{"title":"Hematology"}],"part":{"year":"2019","pages":"1393-1401","issue":"6","text":"98(2019), 6, Seite 1393-1401","volume":"98","extent":"9"},"language":["eng"],"id":{"eki":["253389852"],"issn":["1432-0584"],"zdb":["1458429-3"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"253389852","disp":"Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML)Annals of hematology","type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 24.04.2025","Fortsetzung der Druck-Ausgabe","Ungezählte Beil. ab 80.2001: Supplement"],"origin":[{"publisherPlace":"Berlin ; Heidelberg ; New York","dateIssuedKey":"1991","publisher":"Springer","dateIssuedDisp":"1991-"}],"pubHistory":["62, 1 (Februrary 1991)-"],"title":[{"title_sort":"Annals of hematology","subtitle":"organ of: Gesellschaft für Thrombose- und Hämostaseforschung, DGHO, Deutsche Gesellschaft für Hämatologie und Onkologie e.V., ÖGHO, Österreichische Gesellschaft für Hämatologie und Onkologie","title":"Annals of hematology"}]}],"recId":"1667485679","person":[{"role":"aut","given":"Torsten","display":"Keßler, Torsten","family":"Keßler"},{"given":"Carsten","role":"aut","family":"Müller-Tidow","display":"Müller-Tidow, Carsten"}],"language":["eng"]} | ||
| SRT | |a KESSLERTORPHASEIICLI2120 | ||